戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  the expression of cancer/testis antigens in chondrosarcoma.
2  loci may be required for the development of chondrosarcoma.
3 , and one somatic mutation in a patient with chondrosarcoma.
4 osarcoma and one (20%) of five patients with chondrosarcoma.
5 ily located at 9q22-31, in a skeletal myxoid chondrosarcoma.
6 been observed in the myxoid variant of human chondrosarcoma.
7 H1 is recurrently lost in metastatic central chondrosarcoma.
8 e testis, one of melanoma origin, and one of chondrosarcoma.
9 surgical resection grading of periacetabular chondrosarcoma.
10 ic intervention by mutant IDH1 inhibitors in chondrosarcoma.
11  including osteoarthritis, osteosarcoma, and chondrosarcoma.
12 idered in patients with advanced mutant IDH1 chondrosarcoma.
13 lecules shown to be involved in conventional chondrosarcoma.
14 ome of the increased VEGF expression seen in chondrosarcoma.
15 the regulation of VEGF by HDAC4 and Runx2 in chondrosarcoma.
16 y are causes of increased VEGF expression in chondrosarcoma.
17  used as markers of prognostic importance in chondrosarcoma.
18 eutic potential in the future for subsets of chondrosarcoma.
19 oncogene, as a frequent change in high-grade chondrosarcoma.
20 tified in samples of enchondroma and grade 1 chondrosarcoma.
21 ic findings, except for extraskeletal myxoid chondrosarcomas.
22 anges are diagnostic of extraskeletal myxoid chondrosarcomas.
23 xostoses undergo malignant transformation to chondrosarcomas.
24 cases, these exostoses progress to malignant chondrosarcomas.
25 H mutant in mice elicited the development of chondrosarcomas.
26 ibed in multiple tumors and more recently in chondrosarcomas.
27 are, together constituting 10% to 15% of all chondrosarcomas.
28 ns in IDH1 or IDH2 in nearly half of central chondrosarcomas.
29 2 cm or greater strongly indicated secondary chondrosarcomas.
30  for differentiation of osteochondromas from chondrosarcomas.
31 linical findings in conventional and variant chondrosarcomas.
32  (15%), G3 (20%), and dedifferentiated (21%) chondrosarcomas.
33  1 (hPOSTN-001), we stably transfected human chondrosarcoma 1 (hCh-1) cell line with hPOSTN-001 using
34 d leukaemia (20%), cholangiocarcinoma (20%), chondrosarcoma (80%) and glioma (80%).
35 ard to isocitrate dehydrogenase mutations in chondrosarcoma, a disease in which currently available s
36                                Using a human chondrosarcoma and a murine osteoblast cell line, hepara
37 This peptide adheres to and kills cells from chondrosarcoma and cervical and breast cancer cell lines
38 own that VEGF is overexpressed in high grade chondrosarcoma and chondrosarcoma cell lines.
39 tments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is in
40 on remains the cornerstone of management for chondrosarcoma and chordoma.
41 inoma, adenoid cystic carcinoma, meningioma, chondrosarcoma and fibromyxoid sarcoma.
42                Two patients with progressive chondrosarcoma and melanoma had stable disease lasting a
43 y after resection of human cell line-derived chondrosarcoma and patient-derived xenograft liposarcoma
44 H2 are initiating events in the evolution of chondrosarcoma and several other cancer types.
45     Loss of heterozygosity (LOH) analysis of chondrosarcomas and chondroblastomas revealed multiple L
46 rentiated, 23 clear cell, and 23 mesenchymal chondrosarcomas and performed immunohistochemistry to st
47 ns (eg, cemento-ossifying fibroma and myxoid chondrosarcoma) and the association of established trans
48                           Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multip
49 rphic rhabdomyosarcoma, one dedifferentiated chondrosarcoma, and one malignant peripheral nerve sheat
50  including osteosarcomas, rhabdomyosarcomas, chondrosarcomas, and liposarcomas.
51  gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of
52                           As in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bc
53                                              Chondrosarcomas are a group of tumors that fall into thi
54                                              Chondrosarcomas are a heterogeneous group of bone and so
55 ed genome-wide CpG methylation sequencing of chondrosarcoma biopsies and found that IDH mutations wer
56 ), grade 3 (80%), and dedifferentiated (29%) chondrosarcomas, but was not found in any samples of enc
57 sive genomic analyses of 49 individuals with chondrosarcoma (cases).
58 n the pericellular matrix of transfected rat chondrosarcoma cell and primary human chondrocytes.
59 bp segment with recombinant Sox9 or with rat chondrosarcoma cell extracts, confirming the binding of
60 2 expression and its potential role in human chondrosarcoma cell invasion and metastasis have yet to
61 P-12 or MMP-12 overexpression can potentiate chondrosarcoma cell invasion in vitro and the lung colon
62 l therapeutic strategies that interfere with chondrosarcoma cell invasion may be identified.
63 pursued this possibility using the Swarm rat chondrosarcoma cell line (RCS-LTC) found to express high
64 inity IL-1R sites were identified in a human chondrosarcoma cell line by means of 125I-IL-1beta bindi
65 n of recombinant CRYBP1 in a transfected rat chondrosarcoma cell line inhibited Col2a1 enhancer activ
66 solated human articular chondrocytes and the chondrosarcoma cell line SW-1353 were activated with pol
67 resulted in reduced promoter activity in the chondrosarcoma cell line SW1353 as shown by CpG-free luc
68         Sox9 associates with CBP/p300 in the chondrosarcoma cell line SW1353 via its carboxyl termini
69 red chondrocytes, a stable long-term culture chondrosarcoma cell line, as well as Chinese hamster ova
70 lternative isoform of HBP1 in a heterozygote chondrosarcoma cell line, in a CRISPR-edited osteosarcom
71                                The Swarm rat chondrosarcoma cell line, RCS-LTC, deposits an extracell
72                       SW-1353 cells, a human chondrosarcoma cell line, were stimulated with IL-1beta,
73 of the NT2 expression vector in RSC cells, a chondrosarcoma cell line.
74 sed to compare gene expression between human chondrosarcoma cell lines and normal cartilage.
75 CH1 was not up-regulated or overexpressed in chondrosarcoma cell lines exposed to inflammatory stimul
76 -3 mimetic ABT-737 rendered dedifferentiated chondrosarcoma cell lines sensitive to doxorubicin or ci
77                                              Chondrosarcoma cell lines were used to test for potentia
78 erexpressed in high grade chondrosarcoma and chondrosarcoma cell lines.
79                   First, we found that human chondrosarcoma cells (SW1353) have high expression of av
80 F repressed COMP gene expression in both rat chondrosarcoma cells and bone morphogenetic protein-2-tr
81 nase 1 (MMP-1) in articular chondrocytes and chondrosarcoma cells and found that IL-1 induction of MM
82 In this study, transient transfection of rat chondrosarcoma cells and NIH-3T3 fibroblasts demonstrate
83 MT1-MMP messenger RNA (mRNA) is expressed in chondrosarcoma cells and OA chondrocytes.
84 pression of c/EBPbeta, SOX9, and p300 in rat chondrosarcoma cells and primary human articular chondro
85 ly complete loss of the enhancer activity in chondrosarcoma cells and transgenic mice.
86 HrP also increased Col2a1 mRNA levels in rat chondrosarcoma cells as well as 10T1/2 mesenchymal cells
87 ncreased promoter activity of Col11a2 in rat chondrosarcoma cells but not in either BalB/3T3 cells or
88         IGF-2-, VEGF-B- or VEGF-D-stimulated chondrosarcoma cells display markedly higher migratory a
89 umor necrosis factor alpha (TNFalpha) in rat chondrosarcoma cells increased Mid1, oxidative stress di
90 the activation of the RhoA pathway in SW1353 chondrosarcoma cells increased SOX9(Ser181) phosphorylat
91            Addition of TIMP-3 to HTB94 human chondrosarcoma cells increased the release of sLRP-1 fra
92  We show that reduced expression of HDAC4 in chondrosarcoma cells increases expression of Runx2 leadi
93 BM40 signal peptide in HEK-293 cells and rat chondrosarcoma cells revealed that the BM40 signal pepti
94                                        Human chondrosarcoma cells stimulated with inflammatory cytoki
95                                 Human SW1353 chondrosarcoma cells were transfected with constructs co
96                                          Rat chondrosarcoma cells were transiently transfected with c
97 an articular chondrocytes (HACs) and SW-1353 chondrosarcoma cells were treated with cytokines and TSA
98                                SW-1353 human chondrosarcoma cells were used to study the effects of L
99                                           In chondrosarcoma cells, MMP-1 induction depends on p38 and
100                         In transfected human chondrosarcoma cells, this process is not autoproteolyti
101 ded extracellular network in cultures of rat chondrosarcoma cells.
102  displayed a reduced rate of uptake by HTB94 chondrosarcoma cells.
103 MMP-12) expression and its activity in human chondrosarcoma cells.
104 tein response and cell death pathways in rat chondrosarcoma cells.
105  and biochemical analyses of FGF-treated rat chondrosarcoma chondrocytes, we show that FGF inhibits c
106        Erk activity in FGF2-treated RCS (rat chondrosarcoma) chondrocytes or human primary chondrocyt
107 on and FGF-induced growth arrest of RCS (rat chondrosarcoma) chondrocytes.
108                                              Chondrosarcoma (CS) is a rare cancer, but it is the seco
109                   The pathogenesis of myxoid chondrosarcoma (CS) is poorly understood.
110 ow-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS).
111 thelial carcinoma (n = 2), multiple myeloma, chondrosarcoma, cutaneous squamous cell carcinoma, and s
112                                 One sporadic chondrosarcoma demonstrated LOH for EXT1 and EXT3, while
113 ll line, RCS-LTC (derived from the Swarm rat chondrosarcoma), deposits a copious extracellular matrix
114       Primary bone tumors, osteosarcomas and chondrosarcomas, derive from mesenchymal stem cells comm
115       In xenograft models of liposarcoma and chondrosarcoma, DOX-loaded meshes (DoM) increased overal
116         A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characte
117 tionable; and late recurrences of clear cell chondrosarcomas emphasize the need for long-term follow
118               More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in ei
119                            Two patients with chondrosarcoma experienced durable partial responses to
120 lts of 15 frozen tumor samples of high-grade chondrosarcoma for chromosome 8 are presented.
121 erein that, in contrast to osteosarcomas and chondrosarcomas, for which OSM was cytostatic, OSM induc
122 Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic d
123 ents; mean age, 23.4 years) and 34 secondary chondrosarcomas (from 27 male patients and seven female
124                  We have designed a targeted chondrosarcoma gene therapy using a bacteriophage (phage
125  demographic data, histologic diagnosis, and chondrosarcoma grade were recorded.
126 -grade gliomas, acute myeloid leukaemia, and chondrosarcomas, has been the identification of early-oc
127 med in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) cells, and NIH/3T3 cells showed tha
128 s of c-fos oncogene-induced osteosarcoma and chondrosarcoma in addition to c-Fos-inducible systems in
129 We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib
130 ongly expressed in joint cartilage, we found chondrosarcoma in the knee joint and remarkable defects
131                                              Chondrosarcoma is a cartilage-forming bone tumor, well k
132                                              Chondrosarcoma is a heterogeneous collection of malignan
133                                              Chondrosarcoma is a primary bone tumor with a dismal pro
134 s have established that extraskeletal myxoid chondrosarcoma is a unique entity defined by the presenc
135           The histopathologic variability of chondrosarcomas is reflected in the complexity and lack
136                             In patients with chondrosarcoma, ivosidenib showed minimal toxicity, subs
137 ukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, led to intense discovery efforts to del
138 droblastoma and giant cell tumour of bone to chondrosarcoma, malignant peripheral nerve sheath tumour
139            CSAGE and TRAG-3 are expressed in chondrosarcoma, melanoma, and cartilage and testis, but
140 re osteosarcoma (n = 20), lymphoma (n = 18), chondrosarcoma (n = 16), and giant cell tumor (n = 16).
141 y HIF-1alpha, immunohistochemical studies of chondrosarcoma nodules were conducted and revealed that
142 metastases to the uterine venous plexus from chondrosarcoma of the sacrum.
143                        In skeletal (central) chondrosarcomas of varying histopathologic types, the cy
144           By multivariate analysis, grade of chondrosarcoma (P = .026) was the only factor to reach s
145 eukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients.
146 igated such a role for ADAMTS-3 in Swarm rat chondrosarcoma RCS-LTC cells, which fail to process the
147 bits chondrocyte proliferation both in a rat chondrosarcoma (RCS) cell line and in primary murine cho
148  dramatically inhibited proliferation of rat chondrosarcoma (RCS) cells and arrested their cell cycle
149 oter activity in transiently transfected rat chondrosarcoma (RCS) cells and mouse primary chondrocyte
150 sient-transfection analyses performed in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) c
151 K1/2 or the p38 MAPK pathways applied to rat chondrosarcoma (RCS) chondrocytes significantly prevente
152 ion, n = 12; expansion, n = 9) with advanced chondrosarcoma received ivosidenib (women, n = 8; median
153 benefit of chemotherapy for dedifferentiated chondrosarcomas remains questionable; and late recurrenc
154                                           In chondrosarcoma research, abnormalities in hereditary mul
155 l lung, thyroid, and ovarian carcinomas, and chondrosarcoma, respectively.
156 e 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncome
157 tation is the first of its kind described in chondrosarcoma, serving as an identifying marker of chon
158         In vivo, mice with established human chondrosarcoma showed suppression of tumors upon repetit
159  apoptosis-inducing ligand (Apo2L/TRAIL) for chondrosarcoma, small molecule inhibitor crizotinib for
160 esenchymal, clear cell, and dedifferentiated chondrosarcoma subtypes are extremely rare, together con
161 h p-SMAD2 and PAI-1 was highly active in all chondrosarcoma subtypes, which suggests that TGFbeta inh
162 s as a possible therapeutic strategy in rare chondrosarcoma subtypes.
163 alignancies is an uncommon but real risk for chondrosarcoma survivors; the benefit of chemotherapy fo
164            In human embryonic kidney 293 and chondrosarcoma SW 1353 cells, recombinant pro-CNP was co
165 r distinguishing benign osteochondromas from chondrosarcomas, the sensitivities and specificities wer
166 , selective, and efficient tool for targeted chondrosarcoma therapy.
167                             The prognosis of chondrosarcomas traditionally correlates with histologic
168 g role for targeting Bcl-2 family members in chondrosarcoma treatment, irrespective of the subtype.
169                                      A third chondrosarcoma underwent LOH for EXT1 and chromosome 3q.
170 IGCNB biopsy histology revealed a high-grade chondrosarcoma while the surgical resection histology re

 
Page Top